<DOC>
	<DOCNO>NCT02501902</DOCNO>
	<brief_summary>This Phase 1 , open label , multi center , multiple dose , dose escalation , safety , pharmacokinetic pharmacodynamic study palbociclib combination nab-P , sequential cohort adult patient mPDAC , MTD expansion cohort ( ) . Approximately 30-60 patient expect enrol overall study .</brief_summary>
	<brief_title>Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC</brief_title>
	<detailed_description>The study 2 part : • Part A ( Dose-Escalation Cohorts ) : Consecutive cohort patient receive escalate dos oral palbociclib combination intravenous nab-P 28-day cycle , order estimate MTD ( ) combination . The starting dose 75 mg palbociclib , 100 mg/m2 nab-P . The observation period dose-limiting toxicity ( DLTs ) Day 1 Day 28 . Pharmacokinetic ( PK ) pharmacodynamic ( PD ) property palbociclib nab-P also assess . Up approximately 30 patient enrol . The criterion dose escalation base modify toxicity probability interval ( mTPI ) method . • Part B [ MTD Expansion Cohort ( ) ] : When MTD ( ) palbociclib plus nab-P estimate confidence , enrollment proceed 1 2 MTD expansion cohort ( ) 20 patient MTD ( ) . The objective MTD expansion cohort ( ) provide additional information safety , tolerability , biomarkers , PD activity , PK/PD relationship combination regimen order determine RP2D . The MTD expansion cohort ( ) enroll patient receive previous treatment metastatic disease order evaluate preliminary activity combination target patient population . All patient ( Part A B ) receive nab-P intravenously weekly 3 week 28-day cycle . Palbociclib oral dose daily Days 1-21 28-day cycle . To allow PK evaluation nab-P administer alone , nab-P administer Day -2 Cycle 1 . Subsequent cycle administer nab-P palbociclib Day 1 . Alternate dose schedule palbociclib may explore base emerge PK , PD , safety data . Patients treat long clinically benefit investigational product without unacceptable toxicity , objective disease progression , withdrawal consent . A modified visit schedule implement patient investigational product 2 year .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Histologically cytologicallyconfirmed metastatic pancreatic ductal adenocarcinoma . Availability tumor tissue specimen . If archive tumor tissue available , de novo biopsy require patient participation . Karnofsky Performance Status 70 great . Adequate Bone Marrow , Renal , Liver Function . Prior treatment CDK 4/6 inhibitor . Prior treatment nabP treatment metastatic disease . Patients know CNS metastasis , carcinomatous meningitis , leptomeningeal disease indicate clinical symptom , cerebral edema , and/or progressive growth . Diagnosis malignancy within 3 year prior enrollment , except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix . QTc &gt; 480 msec , family personal history long short QT syndrome , Brugada syndrome know history QTc prolongation , Torsade de Pointes . Uncontrolled electrolyte disorder . Cardiac pulmonary disorder within 6 month enrollment . Known human immunodeficiency virus infection . History interstitial lung disease pneumonitis . Other severe acute chronic medical psychiatric condition may increase risk associate study participation . History allergic reaction attribute compound similar chemical biologic composition nabP . Difficulty swallow capsule requirement feed tube . Previous highdose chemotherapy require stem cell rescue . Pregnant female patient ; breastfeed female patient ; male patient partner currently pregnant . Active inflammatory gastrointestinal disease , Active bleed disorder past 6 month . Patients treat within last 7 day prior start IP strong/moderate CYP3A4 inhibitor , strong/moderate CYP3A4 inducer , CYP2C8 inhibitor , strong/moderate CYP2C8 inducer , drug know prolong QT interval .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Ibrance , palbociclib , Abraxane , nab-paclitaxel , pancreas ,</keyword>
</DOC>